A comprehensive view of Oral Medicines / Supplements. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Roche's oral Alecensa for ALK-positive early-stage lung cancer treatment following successful Phase 3 trial; trial results show Alecensa reduced the risk of disease recurrence or death by 76%
Published: April 19, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
AbbVie announces late-breaking data at AAN supporting long-term safety and efficacy of oral Atogepant QULIPTA for preventive treatment of migraine; 70% of subjects achieved over 50% reduction in monthly migraine days
Published: April 12, 2024 by AbbVie Inc.
The FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine) for adolescents aged 12 and above for the treatment of HIV-1 infection; Dovato offers a single-tablet, two-drug oral regimen for HIV therapy
Published: April 08, 2024 by GSK Group (GlaxoSmithKline)
Boehringer Ingelheim and Eli Lilly report results from EMPACT-MI Phase 3 trial of Jardiance (empagliflozin)
Published: April 06, 2024 by Eli Lilly & Co.
Bristol Myers BMY's late-stage study on Zeposia, an oral drug for Crohn's disease, fails to achieve its primary endpoint in clinical trials; the company did not disclose specific details or future plans for the drug
Published: April 01, 2024 by Zack's Commentary

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count